SCHEMBL3866153

SCHEMBL3866153

CSc1ccc(-c2cc(/C=C/C(=O)O)nn2C2CCCCC2)cc1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTGS2 P35354 2/20 0.46
FABP3 P05413 3/20 0.38
FABP4 P15090 3/20 0.38
S1PR1 P21453 2/20 0.37
KCNJ6 P48051 3/20 0.35
KCNJ3 P48549 3/20 0.35
KCNJ5 P48544 2/20 0.35
TBXA2R P21731 1/20 0.34
PTGER3 P43115 1/20 0.34
PTGER2 P43116 1/20 0.34
PTGDR Q13258 1/20 0.34
KCNH2 Q12809 2/20 0.34
ALDH1A1 P00352 1/20 0.34
LMNA P02545 1/20 0.34
RARB P10826 1/20 0.34
CNR1 P21554 1/20 0.34
GCGR P47871 1/20 0.33
NR1H4 Q96RI1 1/20 0.33
NR3C2 P08235 1/20 0.32
MAPK13 O15264 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3883647 0.86 PTGS2 (0.47) PTGS2FABP3FABP4S1PR1KCNJ6
SCHEMBL4001179 0.86 PTGS2 (0.47) PTGS2FABP3FABP4S1PR1KCNJ6
SCHEMBL3868895 0.83 PTGS2 (0.52) PTGS2FABP3FABP4KCNJ6KCNJ3
SCHEMBL4958421 0.82 RARB (0.39) PTGS2KCNJ6KCNJ3KCNJ5TBXA2R
SCHEMBL3980093 0.82 PTGS2 (0.44) PTGS2FABP3FABP4KCNH2ALDH1A1
SCHEMBL12860103 0.81 FABP3 (0.47) PTGS2FABP3FABP4S1PR1ALDH1A1
SCHEMBL1131603 0.78 FABP3 (0.46) PTGS2FABP3FABP4PTGER3PTGDR
SCHEMBL1131599 0.78 FABP3 (0.46) PTGS2FABP3FABP4PTGER3PTGDR
SCHEMBL1131610 0.76 PTGS2 (0.46) PTGS2FABP3FABP4S1PR1KCNJ6
SCHEMBL1131606 0.76 PTGS2 (0.46) PTGS2FABP3FABP4S1PR1KCNJ6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090005350-A1 CYCLOOXYGENASE-2 SELECTIVE INHIBITORS, COMPOSITIONS AND METHODS OF USE NITROMED, INC. (US) 2009-01-01 US disclosed
US-7442802-B2 Cyclooxygenase-2 selective inhibitors, compositions and methods of use NITROMED, INC. (US) 2008-10-28 US disclosed
US-20060194861-A1 Cyclooxygenase-2 selective inhibitors, compositions and methods of use NITROMED, INC. (US) 2006-08-31 US disclosed
US-7087630-B2 Cyclooxygenase 2 selective inhibitors, compositions and methods of use NITROMED, INC. (US) 2006-08-08 US disclosed
EP-1534683-A4 CYCLOOXYGENASE-2 SELECTIVE INHIBITORS, COMPOSITIONS AND METHODS OF USE NITROMED INC (US) 2005-08-24 EP disclosed
EP-1534683-A2 CYCLOOXYGENASE-2 SELECTIVE INHIBITORS, COMPOSITIONS AND METHODS OF USE Nitromed, Inc. (US) 2005-06-01 EP disclosed
US-20040053985-A1 Cyclooxygenase-2 selective inhibitors, compositions and methods of use NITROMED, INC. 2004-03-18 US disclosed
WO-2004002409-A2 CYCLOOXYGENASE-2 SELECTIVE INHIBITORS, COMPOSITIONS AND METHODS OF USE NITROMED, INC. (US) 2004-01-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040053985-A1 Cyclooxygenase-2 selective inhibitors, compositions and methods of use PTGS2, PTGIS, PTGES2 PTGS2 1/4885FABP3 188/4885FABP4 2104/4885
US-20060194861-A1 Cyclooxygenase-2 selective inhibitors, compositions and methods of use PTGS2, PTGIS, PTGES2 PTGS2 1/4885FABP3 188/4885FABP4 2104/4885
US-20090005350-A1 CYCLOOXYGENASE-2 SELECTIVE INHIBITORS, COMPOSITIONS AND METHODS OF USE PTGS2, PTGIS, PTGES2 PTGS2 1/4885FABP3 188/4885FABP4 2104/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.